NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis $10.30 +0.22 (+2.18%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$10.32 +0.02 (+0.24%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Keros Therapeutics Stock (NASDAQ:KROS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Keros Therapeutics alerts:Sign Up Key Stats Today's Range$9.55▼$10.5550-Day Range$9.17▼$11.9552-Week Range$8.98▼$22.55Volume167,041 shsAverage Volume189,597 shsMarket Capitalization$202.09 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingModerate Buy Company Overview Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-β) protein family. Its research has centered on disorders involving blood-cell production and muscle function. The company’s pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions. These programs are investigational and are not approved treatments. Founded in 2015 and based in Lexington, Massachusetts, Keros conducts research and clinical development with the aim of serving patients in multiple markets. Cofounder Jasbir Seehra has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Keros Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreKROS MarketRank™: 3.116662307085 of 5 starsKeros Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 349th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingKeros Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKeros Therapeutics has a consensus price target of $20.00, representing about 94.2% upside from its current price of $10.30.Amount of Analyst CoverageKeros Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Keros Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($3.73) to ($5.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.27% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 7.06.Change versus previous monthShort interest in Keros Therapeutics has recently decreased by 4.45%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.65 News SentimentKeros Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Keros Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for KROS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,985.00 in company stock.Percentage Held by Insiders12.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KROS Stock News HeadlinesFY2026 EPS Forecast for Keros Therapeutics Lifted by AnalystNovember 12 at 2:13 AM | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Upgraded to Hold at Wall Street ZenNovember 9, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 14 at 1:00 AM | Weiss Ratings (Ad)Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), ANI Pharmaceuticals (ANIP) and Keros Therapeutics (KROS)November 7, 2026 | theglobeandmail.comKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsNovember 6, 2026 | markets.businessinsider.comKeros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in PlaySeptember 30, 2026 | tipranks.comKeros Therapeutics Expects $20 Million Milestone Payment From TakedaSeptember 29, 2026 | finance.yahoo.comKeros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 TrialSeptember 29, 2026 | quiverquant.comQSee More Headlines KROS Stock Analysis - Frequently Asked Questions How have KROS shares performed this year? Keros Therapeutics' stock was trading at $20.36 at the beginning of the year. Since then, KROS stock has decreased by 49.4% and is now trading at $10.30. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) released its earnings results on Thursday, November, 5th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $1.66. The firm earned $40.01 million during the quarter, compared to analysts' expectations of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative trailing twelve-month return on equity of 21.85%. Is Keros Therapeutics doing a stock buyback? Keros Therapeutics' Board of Directors initiated a share repurchase plan on Wednesday, September 9th 2026, which permits the company to repurchase $5 million in outstanding shares, according to EventVestor. This means that the company could reacquire up to 2.3% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's board believes its shares are undervalued. When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $90 million in an initial public offering on Wednesday, April 8th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Keros Therapeutics' major shareholders? Top institutional investors of Keros Therapeutics include Nantahala Capital Management LLC (7.59%), State Street Corp (2.76%), Empowered Funds LLC (0.67%) and Marshall Wace LLP (0.59%). Insiders that own company stock include Carl L Gordon, Carl L Gordon, Annita Tanini, Lorena Raquel Lerner, Jean Jacques Bienaime, Charles W Newton, Julius Knowles, Alpna Seth, Nima Farzan, Pontifax Management 4 GP (20 and Adar1 Capital Management, Llc. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Oracle (ORCL), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Broadcom (AVGO), Marvell Technology (MRVL) and Micron Technology (MU). Company Calendar Last Earnings11/05/2026Today11/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 KROS's financial health is in the Red zone, according to TradeSmith. KROS has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KROS CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees92Year Founded2015Price Target and Rating Average Price Target for Keros Therapeutics$20.00 High Price Target$23.00 Low Price Target$18.00 Potential Upside/Downside+94.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$87.01 million Net Margins-256.60% Pretax Margin-153.25% Return on Equity-21.85% Return on Assets-19.83% Debt Debt-to-Equity RatioN/A Current Ratio18.14 Quick Ratio21.96 Sales & Book Value Annual Sales$244.06 million Price / Sales0.83 Cash Flow$4.62 per share Price / Cash Flow2.23 Book Value$14.22 per share Price / Book0.72Miscellaneous Outstanding Shares19,620,000Free Float17,151,000Market Cap$202.09 million OptionableOptionable Beta1.13 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:KROS) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
